Učitavanje...

Novel C-Terminal Hsp90 Inhibitor for Head and Neck Squamous Cell Cancer (HNSCC) with in vivo Efficacy and Improved Toxicity Profiles Compared with Standard Agents

BACKGROUND: Current therapies for HNSCC, especially platinum agents, are limited by their toxicities and drug resistance. This study evaluates a novel C-terminal Hsp90 inhibitor (CT-Hsp90-I) for efficacy and toxicity in vitro and in vivo in an orthotopic HNSCC model. Our hypothesis is that C-termina...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Surg Oncol
Glavni autori: Cohen, Stephanie M., Mukerji, Ridhwi, Samadi, Abbas K., Zhao, Huiping, Blagg, Brian S. J., Cohen, Mark S.
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5828498/
https://ncbi.nlm.nih.gov/pubmed/21837531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-011-1971-1
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!